Dennis Brandl, President, at BR&L Consulting, spoke with BioPharm International about what should be expected when transitioning from paper to EBR.
Dennis Brandl, President, at BR&L Consulting, spoke with BioPharm International about what should be expected when transitioning from paper to EBR.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.